Amneal Pharmaceuticals Inc banner
A

Amneal Pharmaceuticals Inc
F:2DT

Watchlist Manager
Amneal Pharmaceuticals Inc
F:2DT
Watchlist
Price: 10.3 EUR -3.74% Market Closed
Market Cap: €3.2B

Amneal Pharmaceuticals Inc
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Amneal Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
A
Amneal Pharmaceuticals Inc
F:2DT
Other Long-Term Assets
$57.8m
CAGR 3-Years
-18%
CAGR 5-Years
21%
CAGR 10-Years
-2%
Johnson & Johnson
NYSE:JNJ
Other Long-Term Assets
$19.3B
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Other Long-Term Assets
$8.2B
CAGR 3-Years
42%
CAGR 5-Years
20%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Other Long-Term Assets
$19.3B
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
14%
Merck & Co Inc
NYSE:MRK
Other Long-Term Assets
$17.8B
CAGR 3-Years
30%
CAGR 5-Years
13%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Other Long-Term Assets
$17B
CAGR 3-Years
33%
CAGR 5-Years
22%
CAGR 10-Years
23%
No Stocks Found

Amneal Pharmaceuticals Inc
Glance View

Market Cap
3.2B EUR
Industry
Pharmaceuticals

Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale. Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.

2DT Intrinsic Value
15.6 EUR
Undervaluation 34%
Intrinsic Value
Price €10.3
A

See Also

What is Amneal Pharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
57.8m USD

Based on the financial report for Dec 31, 2025, Amneal Pharmaceuticals Inc's Other Long-Term Assets amounts to 57.8m USD.

What is Amneal Pharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-2%

Over the last year, the Other Long-Term Assets growth was -4%. The average annual Other Long-Term Assets growth rates for Amneal Pharmaceuticals Inc have been -18% over the past three years , 21% over the past five years , and -2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett